|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
4,900,000 |
Market
Cap: |
14.70(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.000001 - $0.000001 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile VioQuest Pharmaceuticals is engaged in acquiring technologies for purposes of development and commercialization of pharmaceutical drug candidates for the treatment of oncology and antiviral diseases and disorders. Co. operates under one distinct business unit: Drug Development. As of Dec 31 2006, Co. had the right to develop and commercialize two oncology drug candidates, VQD-001 and VQD-002. In collaboration with the U.S. Army, Co. is developing VQD-001, a pentavalent antimonial drug for the treatment of leishmaniasis. Co. is also developing VQD-002, a nucleoside analog, for the treatment of metastatic and refractory solid tumors including colorectal, pancreatic, breast and ovarian tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|